週边药物释放型球囊扩张导管市场（依药物类型、球囊长度、涂层技术及最终用户划分）－2026-2032年全球预测

2025 年外周药物释放型球囊扩张导管市场价值为 8.6301 亿美元，预计到 2026 年将增长至 9.4996 亿美元，年复合增长率为 10.69%，到 2032 年将达到 17.5784 亿美元。

关键市场统计数据
基准年 2025	8.6301亿美元
预计年份：2026年	9.4996亿美元
预测年份 2032	1,757,840,000 美元
复合年增长率 (%)	10.69%

週边动脉评分药物释放型球囊扩张导管的全面实施：临床作用、技术基础及相关人员影响

末梢用刻痕药物释放型球囊扩张导管融合了介入技术和标靶药物传递技术，为临床医生治疗复杂的周边动脉疾病提供了新的选择。这些装置结合了机械性斑块修饰和局部抗增殖药物给药，可改善血管准备并维持通畅性，尤其适用于简单球囊血管成形术难以处理的复杂病变。随着临床团队不断优化患者选择和手术流程，这些导管在血管外科医生、介入放射科医生和导管检查室工作人员参与的多学科讨论中发挥着日益重要的作用。

重塑週边血管刻痕药物释放型球囊应用的变革性变化分析：包括手术技术、材料科学和临床路径

週边血管刻痕药物释放型球囊治疗领域正经历一系列变革，这些变革的驱动力来自临床证据、材料科学和手术优化。临床上，对复杂病变亚型的不断积累，使人们对刻痕机制何时比传统血管成形术更具价值，以及药物释放型何时能显着预防血管再阻塞有了更深入的了解。因此，通讯协定的製定和操作者的技术也随之发展，更加註重病变准备、球囊尺寸的选择以及在条件允许的情况下进行血管内影像学检查后的扩张评估。

评估2025年美国关税对週边刻痕药物洗脱球囊的供应链、成本和策略采购的累积影响

2025年美国关税政策为依赖跨境供应链的周边血管器材製造商、经销商和医疗系统引入了新的策略因素。虽然关税本身不会改变器材的临床特性，但它会影响最终到岸成本、供应商选择和库存策略，从而改变采购策略。为此，各机构正在重新评估供应商多元化和物流模式，以降低关税相关中断带来的风险，并确保能够获得满足临床需求的关键器械型号。

对终端用户环境、药物类型、通路、球囊尺寸、长度和涂层技术等因素对临床应用的影响进行分段分析

细分市场分析揭示了不同的临床环境和产品特性如何影响临床环境中设备的选择和使用模式。就终端用户环境而言，门诊手术中心和医院的手术量、人员配备模式和资金限制各不相同，这促使医疗机构优先选择一次性技术或投资于更有限的专业库存。同样，紫杉醇和Sirolimus药物类型之间的差异也会影响临床决策，这取决于当地的安全性认知、临床医生的熟悉程度以及对特定病变亚群疗效的预期。直销和批发分销管道的选择对营运具有重要意义。直销往往有利于促进更紧密的商业临床合作和产品培训，而批发分销则能提供更广泛的覆盖率和库存整合。

从区域观点检视美洲、欧洲、中东和非洲以及亚太市场的临床、监管、报销和供应链的考量因素

区域趋势对週边药物释放型球囊系统的监管路径、报销机制和临床应用率有显着影响。在美洲，手术创新往往与既定的介入治疗模式、医院主导的采购流程以及复杂的报销环境密切相关。这种报销环境会根据支付方的接受程度和编码的清晰度，促进或限制其应用。欧洲、中东和非洲地区的监管和采购环境各不相同，国家和地区层级的卫生技术评估（HTA）框架会影响引进週期。本地的生产和分销协议会对市场进入和定价动态产生重大影响。亚太地区涵盖了从高度监管的成熟市场到快速发展的医疗基础设施，市场类型多样化。在许多地区，对成本效益高的治疗方法和高容量手术能力的关注，决定了器械的选择和临床应用的速度。

从公司观点对血管器材产业的策略联盟、产品创新、製造韧性和竞争差异化进行深入分析

该专业领域的公司正透过渐进式产品开发、策略联盟和週期性整合相结合的方式，在创新和规模化之间寻求平衡。大型医疗设备製造商的产品系列优先考虑成熟的平台技术和广泛的商业性覆盖，而规模较小的专业公司则专注于改进特定特性，例如刻痕元件几何形状、药物涂层稳定性以及新型沉积方法。医疗设备製造商越来越多地与契约製造组织 (CMO) 合作，以加快产品改进週期并控制与检验涂层製程相关的资本密集度。

为领导者提供建议，以加快临床应用、增强供应链韧性、协调监管方法并维持血管器械领域的创新。

为了推动週边血管刻痕药物释放型球囊技术的持续应用，产业领导者应优先考虑整合临床检验、供应保障和监管前瞻性的协作模式。首先，各机构应投入资源进行严格的操作培训和结果追踪，以检验该设备在特定患者群体中的有效性。这将有助于增强临床医师的信心，并促进内部达成共识，推动该设备的推广应用。其次，采购和供应链团队应努力实现筹资策略多元化，并制定紧急时应对计画，以确保关键设备配置的供应，同时最大限度地降低地缘政治因素和关税带来的干扰。

一套清晰的调查方法，明确规定了资料来源、相关人员访谈、证据综合、检验过程以及所适用的伦理标准。

本分析的调查方法整合了多方面的证据，以得出关于医疗设备现状的一致且可验证的检验。主要证据来自对临床负责人、采购经理和监管专家的结构化访谈，并辅以医疗设备附加檔审查和已发布的监管文件。二级资讯来源包括同行评审的临床文献、临床学会指南和手术最佳实践出版物，以确保对医疗设备性能的讨论基于当前的临床经验和标准。

简明扼要地总结了临床、技术、监管和商业性观点，以指南策略决策和未来研究重点。

这项综合分析结合了临床、技术、监管和商业性观点，旨在为週边刻痕药物释放型洗脱球囊系统的相关人员提供实际决策依据。临床证据和外科医生经验表明，在某些情况下，将机械刻痕与局部药物输送相结合可以带来显着的手术获益，尤其是在易发生弹性回缩和血管再阻塞的解剖结构中。涂层化学和可控刻痕机制的技术进步缩小了性能与操作性之间的传统差距。同时，监管机构日益关注，凸显了可靠的安全性数据和上市后监测数据的重要性。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 週边血管药物释放型球囊扩张导管市场（依药物类型划分）

• 紫杉醇
• Sirolimus

9. 週边血管药物释放型球囊扩张导管市场（依球囊长度划分）

• 超过 40 毫米
• 21～40mm
• 20毫米或更小

10. 週边血管药物释放型球囊扩张导管市场（依涂层技术划分）

• 双层型
• 不含聚合物
• 单层

11. 依最终用户分類的周边药物药物释放型球囊扩张导管市场

• 门诊手术中心
• 医院

12. 週边药物药物释放型球囊扩张导管市场（依地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

13. 週边药物药物释放型球囊扩张导管市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

14. 各国外周药物药物释放型球囊扩张导管市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

15. 美国週边药物释放型球囊扩张导管市场

第十六章 中国週边血管药物释放型球囊扩张导管市场

第十七章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Aachen Resonance GmbH
• Abbott Laboratories
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• BrosMed Medical Co., Ltd.
• Cardionovum GmbH
• Concept Medical Research Private Limited
• Cook Medical LLC
• Cordis Corporation
• Eurocor GmbH
• iVascular, SLU
• Koninklijke Philips NV
• MedAlliance SA
• Medtronic plc
• Meril Life Sciences Private Limited
• MicroPort Scientific Corporation
• Teleflex Incorporated
• Terumo Corporation

The Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market was valued at USD 863.01 million in 2025 and is projected to grow to USD 949.96 million in 2026, with a CAGR of 10.69%, reaching USD 1,757.84 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 863.01 million
Estimated Year [2026]	USD 949.96 million
Forecast Year [2032]	USD 1,757.84 million
CAGR (%)	10.69%

Comprehensive introduction to peripheral scoring drug-eluting balloon dilation catheters, their clinical role, technological foundations, and stakeholder impacts

Peripheral scoring drug-eluting balloon dilation catheters occupy a distinct intersection of interventional technique and targeted pharmacologic delivery, offering clinicians an alternative strategy for addressing complex peripheral arterial disease. These devices combine mechanical plaque modification with local antiproliferative drug administration to improve vessel preparation and support sustained patency, particularly in challenging lesions where plain balloon angioplasty has limitations. As clinical teams refine patient selection and procedural workflows, these catheters increasingly feature in multidisciplinary conversations involving vascular surgeons, interventional radiologists, and catheterization laboratory staff.

From a technological standpoint, the devices represent a convergence of advances in balloon design, coating science, and delivery precision. Innovations in scoring elements seek to optimize controlled plaque fracture while minimizing vessel trauma, and drug-eluting formulations aim to suppress neointimal hyperplasia at the site of injury. Together, these attributes influence procedural planning, post-procedure management, and the expectations of long-term device performance. Consequently, stakeholders across clinical, procurement, and regulatory functions must weigh clinical efficacy, procedural complexity, and device characteristics when considering adoption and integration into care pathways.

Analysis of transformative shifts reshaping peripheral scoring drug-eluting balloon use including procedural techniques, material science, and clinical pathways

The landscape for peripheral scoring drug-eluting balloon therapy is experiencing a set of transformative shifts driven by clinical evidence, materials science, and procedural optimization. Clinically, growing experience with complex lesion subsets has sharpened understanding of when scoring mechanisms add value relative to conventional angioplasty, and when drug elution provides measurable benefit in limiting restenosis. As a result, protocol development and operator technique have evolved, emphasizing lesion preparation, appropriate balloon sizing, and post-dilation assessment using intravascular imaging where available.

Technological progress in coating chemistries and deposition techniques has improved drug transfer efficiency and reduced downstream particulate concerns, influencing regulatory scrutiny and hospital procurement decisions. Concurrently, manufacturing advances and supply chain rationalization have enabled more consistent product quality and smaller-batch innovation from specialist manufacturers. Taken together, these forces are shifting the balance between standalone scoring balloons, drug-eluting variants, and hybrid approaches, prompting healthcare systems to revisit training, capital planning, and outcome measurement to ensure that device selection aligns with evolving standards of care.

Evaluation of the cumulative impact of United States tariffs in 2025 on peripheral scoring drug-eluting balloon supply chains, costs, and strategic sourcing

The introduction of United States tariffs in 2025 has introduced an additional strategic dimension for manufacturers, distributors, and health systems that rely on cross-border supply chains for peripheral vascular devices. While tariffs do not change the clinical profile of devices, they alter procurement calculus by affecting landed costs, supplier selection, and inventory strategies. In response, organizations are reassessing supplier diversity and logistical models to mitigate exposure to tariff-related disruptions and to preserve access to critical device variants that meet clinical needs.

Practically, procurement teams are undertaking scenario planning that considers alternative manufacturing footprints, nearshoring options, and tiered distribution agreements to sustain availability. Regulatory and compliance functions are coordinating with commercial teams to track tariff classifications and to ensure that device labeling and material disclosures meet customs requirements. For clinical operations, the primary implication is the potential need to validate new suppliers or device lots more frequently, and to update contracted pricing frameworks to reflect changes in total cost of ownership rather than unit price alone. Above all, the tariffs have underscored the value of supply chain transparency and proactive engagement across procurement, regulatory affairs, and clinical leadership.

Segmented insights on how end user environments, drug types, distribution routes, balloon sizes, lengths, and coating technologies shape clinical adoption

Segmentation analysis clarifies how different clinical environments and product characteristics shape device selection and utilization patterns across care settings. When considering end user environments, Ambulatory Surgical Center and Hospital settings each present distinct procedural volumes, staffing models, and capital constraints that influence whether a facility prioritizes single-use disposable technologies or invests in a narrower range of specialized inventory. Likewise, the distinction between Paclitaxel and Sirolimus drug types affects clinical decision-making based on local safety narratives, clinician familiarity, and perceived efficacy in specific lesion subsets. Distribution choices between Direct Sales and Wholesale Distributor channels have operational implications, where direct sales often facilitate tighter commercial-clinical collaboration and product training while wholesale distribution offers broader reach and inventory aggregation.

Device geometry further refines clinical deployment, as balloon diameter categorized as Above Four Mm or Up To Four Mm guides suitability for larger conduit vessels versus smaller distal targets, and length designations of Above Forty Mm, Twenty One To Forty Mm, and Up To Twenty Mm determine treatment strategies for focal versus long-segment disease. Coating technology differentiations-Dual Layer, Polymer Free, and Single Layer-affect drug delivery kinetics, surface interaction with blood elements, and handling characteristics during insertion and deployment. Taken together, these segmentation dimensions inform procurement bundles, clinician training programs, and the design of clinical studies that aim to demonstrate device performance across relevant use cases.

Regional perspectives examining clinical, regulatory, reimbursement, and supply chain considerations across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics exert a strong influence on regulatory pathways, reimbursement mechanics, and clinical adoption rates for peripheral scoring drug-eluting balloon systems. In the Americas, procedural innovation often aligns with robust interventional practice patterns, hospital-based purchasing processes, and a complex reimbursement landscape that can either encourage or constrain use depending on payer acceptance and coding clarity. Europe, Middle East & Africa presents a heterogenous regulatory and procurement environment where national and regional health technology assessment frameworks drive adoption cycles, and where localized manufacturing or distributor arrangements can materially affect market access and pricing negotiation dynamics. Asia-Pacific encompasses diverse markets ranging from highly regulated mature systems to rapidly developing healthcare infrastructures; in many territories, emphasis on cost-effective interventions and high-volume procedural throughput shapes device selection and the pace of clinical uptake.

Across these regions, regulatory expectations for clinical evidence, post-market surveillance, and device labeling differ, which in turn shapes go-to-market strategies. Supply chain considerations vary with geographic concentration of manufacturing hubs, customs regimes, and logistical complexity, demanding differentiated sourcing tactics. Clinical training and investigator networks also display regional patterns, influencing the dissemination of best practices and the speed at which new device iterations achieve meaningful adoption within different healthcare ecosystems.

High-level company-focused insights on strategic partnerships, product innovation, manufacturing resilience, and competitive differentiation in vascular devices

Corporate behavior within this specialized segment reflects a mix of incremental product development, strategic partnerships, and periodic consolidation as companies seek to balance innovation with scale. Leading medical device manufacturers maintain portfolios that prioritize proven platform technologies and wide commercial reach, while smaller specialty firms focus on improving niche attributes such as scoring element geometry, drug-coating stability, or novel deposition methods. Collaboration between device firms and contract manufacturing organizations has increased to accelerate product iteration cycles and to manage capital intensity associated with validated coating processes.

Commercial strategies increasingly emphasize clinical evidence generation, real-world data collection, and clinician education to differentiate offerings in a crowded environment. Firms with strong distribution networks can rapidly deploy training and build procedural volume, whereas companies that invest in manufacturing resilience and robust quality systems are better positioned to respond to supply chain shocks. Additionally, partnerships that pair large-scale commercialization capability with nimble product development have emerged as a common path to scale innovations while ensuring regulatory and reimbursement alignment. Collectively, these trends illustrate how firms are adapting corporate strategy to address both clinical expectations and operational realities.

Recommendations for leaders to accelerate clinical adoption, strengthen supply resilience, align regulatory approaches, and sustain innovation in vascular devices

Industry leaders should prioritize a coordinated approach that aligns clinical validation, supply continuity, and regulatory foresight to drive sustainable adoption of peripheral scoring drug-eluting balloon technologies. First, organizations must invest in rigorous procedural training and outcomes tracking to validate device benefits within their specific patient populations, thereby building clinician confidence and facilitating internal consensus for adoption. Second, procurement and supply chain teams should diversify sourcing strategies and create contingency plans that minimize exposure to geopolitical and tariff-induced disruption while preserving access to critical device configurations.

In parallel, commercial and regulatory functions ought to collaborate on evidence generation that addresses payer concerns and supports favorable reimbursement dialogues. Companies should consider modular product portfolios that allow clinicians to match balloon diameter, length, and coating characteristics to lesion anatomy without excessive inventory burden. Finally, fostering cross-functional partnerships-linking clinical champions, engineering teams, and commercial leads-will accelerate iterative improvements, shorten feedback cycles, and help translate insights from the bedside into next-generation device enhancements and targeted commercialization plans.

Clear research methodology describing data sources, stakeholder interviews, evidence synthesis, validation processes, and applied ethical standards

The methodological approach underpinning this analysis integrates multiple lines of evidence to produce a coherent, verifiable perspective on the device landscape. Primary evidence was obtained through structured interviews with clinical operators, procurement managers, and regulatory specialists, supplemented by device labeling reviews and publicly available regulatory documentation. Secondary sources included peer-reviewed clinical literature, clinical society guidance, and procedural best-practice publications to ensure that device performance discussions are grounded in current clinical experience and standards.

Synthesis employed cross-validation techniques that compared interview insights with published evidence and manufacturer disclosures, and quality assurance steps included triangulating findings across data types to minimize bias. Ethical standards guided stakeholder engagement, ensuring voluntary participation and confidentiality where requested. Finally, interpretation prioritized actionable implications for clinical teams, manufacturers, and procurement leaders, with transparent notes on evidence limitations and areas where further primary investigation would add value.

Concise conclusion synthesizing clinical, technological, regulatory, and commercial perspectives to inform strategic decisions and future research priorities

This synthesis brings clinical, technological, regulatory, and commercial perspectives together to inform practical decision-making for stakeholders involved with peripheral scoring drug-eluting balloon systems. Clinical evidence and operator experience point to scenarios where combined mechanical scoring and localized drug delivery can provide meaningful procedural advantages, particularly in anatomies prone to elastic recoil or restenosis. Technological progress in coating chemistry and controlled scoring mechanisms has narrowed previous gaps in performance and handling, while evolving regulatory attention underscores the importance of robust safety and post-market surveillance data.

Commercially, procurement and supply considerations increasingly factor into device selection, with organizations seeking partners that demonstrate manufacturing reliability and responsive distribution models. Taken as a whole, the sector is maturing: incremental innovation is producing devices that better balance efficacy and deliverability, and stakeholders that align clinical protocols with evidence-based procurement strategies will be best positioned to realize patient and system-level gains. Further targeted research and real-world data collection will continue to refine clinical indications and inform cost-effective deployment strategies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Drug Type

• 8.1. Paclitaxel
• 8.2. Sirolimus

9. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Balloon Length

• 9.1. Above Forty Mm
• 9.2. Twenty One To Forty Mm
• 9.3. Up To Twenty Mm

10. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Coating Technology

• 10.1. Dual Layer
• 10.2. Polymer Free
• 10.3. Single Layer

11. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by End User

• 11.1. Ambulatory Surgical Center
• 11.2. Hospital

12. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market

16. China Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Aachen Resonance GmbH
• 17.6. Abbott Laboratories
• 17.7. B. Braun Melsungen AG
• 17.8. Becton, Dickinson and Company
• 17.9. BIOTRONIK SE & Co. KG
• 17.10. Boston Scientific Corporation
• 17.11. BrosMed Medical Co., Ltd.
• 17.12. Cardionovum GmbH
• 17.13. Concept Medical Research Private Limited
• 17.14. Cook Medical LLC
• 17.15. Cordis Corporation
• 17.16. Eurocor GmbH
• 17.17. iVascular, S.L.U.
• 17.18. Koninklijke Philips N.V.
• 17.19. MedAlliance SA
• 17.20. Medtronic plc
• 17.21. Meril Life Sciences Private Limited
• 17.22. MicroPort Scientific Corporation
• 17.23. Teleflex Incorporated
• 17.24. Terumo Corporation

LIST OF FIGURES

• FIGURE 1. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY PACLITAXEL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SIROLIMUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SIROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY ABOVE FORTY MM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY ABOVE FORTY MM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY ABOVE FORTY MM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY TWENTY ONE TO FORTY MM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY TWENTY ONE TO FORTY MM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY TWENTY ONE TO FORTY MM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY UP TO TWENTY MM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY UP TO TWENTY MM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY UP TO TWENTY MM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DUAL LAYER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DUAL LAYER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DUAL LAYER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY POLYMER FREE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY POLYMER FREE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SINGLE LAYER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SINGLE LAYER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SINGLE LAYER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. AMERICAS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 38. AMERICAS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 39. AMERICAS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 40. AMERICAS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 41. AMERICAS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 42. NORTH AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. NORTH AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 44. NORTH AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 45. NORTH AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 46. NORTH AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 47. LATIN AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 48. LATIN AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 49. LATIN AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 50. LATIN AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 51. LATIN AMERICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 52. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 53. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 57. EUROPE PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 58. EUROPE PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 59. EUROPE PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 60. EUROPE PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 61. EUROPE PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 62. MIDDLE EAST PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. MIDDLE EAST PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 64. MIDDLE EAST PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 65. MIDDLE EAST PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 66. MIDDLE EAST PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 67. AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 68. AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 69. AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 70. AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 71. AFRICA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 72. ASIA-PACIFIC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. ASIA-PACIFIC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 74. ASIA-PACIFIC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 75. ASIA-PACIFIC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 76. ASIA-PACIFIC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 78. ASEAN PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. ASEAN PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 80. ASEAN PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 81. ASEAN PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 82. ASEAN PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 83. GCC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 84. GCC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 85. GCC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 86. GCC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 87. GCC PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 88. EUROPEAN UNION PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 89. EUROPEAN UNION PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 90. EUROPEAN UNION PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 91. EUROPEAN UNION PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 92. EUROPEAN UNION PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 93. BRICS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 94. BRICS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 95. BRICS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 96. BRICS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 97. BRICS PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 98. G7 PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. G7 PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 100. G7 PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 101. G7 PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 102. G7 PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 103. NATO PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 104. NATO PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 105. NATO PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 106. NATO PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 107. NATO PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 110. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 111. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 112. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 113. UNITED STATES PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 114. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 115. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
• TABLE 116. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY BALLOON LENGTH, 2018-2032 (USD MILLION)
• TABLE 117. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY COATING TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 118. CHINA PERIPHERAL SCORING DRUG-ELUTING BALLOON DILATION CATHETER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)